249 related articles for article (PubMed ID: 11380399)
21. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
22. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.
Yavuz AS; Lipsky PE; Yavuz S; Metcalfe DD; Akin C
Blood; 2002 Jul; 100(2):661-5. PubMed ID: 12091362
[TBL] [Abstract][Full Text] [Related]
24. c-kit mutational analysis in paraffin material.
Sotlar K
Methods Mol Biol; 2013; 999():59-78. PubMed ID: 23666690
[TBL] [Abstract][Full Text] [Related]
25. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
26. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
27. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis.
Cairoli R; Grillo G; Beghini A; Cornacchini G; Larizza L; Morra E
Hematol J; 2004; 5(3):273-5. PubMed ID: 15167915
[TBL] [Abstract][Full Text] [Related]
28. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
29. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
30. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
31. Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
[TBL] [Abstract][Full Text] [Related]
32. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
[TBL] [Abstract][Full Text] [Related]
33. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val.
Sperr WR; Walchshofer S; Horny HP; Födinger M; Simonitsch I; Fritsche-Polanz R; Schwarzinger I; Tschachler E; Sillaber C; Hagen W; Geissler K; Chott A; Lechner K; Valent P
Br J Haematol; 1998 Dec; 103(3):740-9. PubMed ID: 9858225
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
35. c-kit mutation in a population of patients with mastocytosis.
Nagata H; Okada T; Worobec AS; Semere T; Metcalfe DD
Int Arch Allergy Immunol; 1997; 113(1-3):184-6. PubMed ID: 9130517
[TBL] [Abstract][Full Text] [Related]
36. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.
Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP
J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565
[TBL] [Abstract][Full Text] [Related]
37. A new c-kit mutation in a case of aggressive mast cell disease.
Pignon JM; Giraudier S; Duquesnoy P; Jouault H; Imbert M; Vainchenker W; Vernant JP; Tulliez M
Br J Haematol; 1997 Feb; 96(2):374-6. PubMed ID: 9029028
[TBL] [Abstract][Full Text] [Related]
38. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.
Molderings GJ; Meis K; Kolck UW; Homann J; Frieling T
Immunogenetics; 2010 Dec; 62(11-12):721-7. PubMed ID: 20838788
[TBL] [Abstract][Full Text] [Related]
40. Mastocytosis: molecular mechanisms and clinical disease heterogeneity.
Metcalfe DD; Akin C
Leuk Res; 2001 Jul; 25(7):577-82. PubMed ID: 11377683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
